About Penta
Who we are
Our Strategy
Our Network
Working Groups
Penta Foundation
Our Staff
Diversity and Inclusion
Annual reports
Our Activities
News & Webinars
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Calls for service
PentaTr@ining
Archivio
Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy.
A randomised trial of resistance testing versus no resistance testing in children with virological failure: the PERA (PENTA 8) trial
Adherence and acceptability of once daily lamivudine and abacavir in HIV-1 infected children
Lower scores of Nelfinavir metabolite M8 were associated with virological failure vertically infected children in the PENTA 7study.
Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data.
Pharmacokinetics of once versus twice daily lamivudine and abacavir. Simplification of combination treatment in HIV-1 infected children (Penta 13)
Relationship between changes in thymic emigrants and cell-associated HIV-1 DNA in HIV-1 infected children initiating antiretroviral therapy